- Home
- DAVA vs ORGO Comparison
DAVA vs ORGO Comparison
Compare DAVA & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- ORGO
- Stock Information
- Founded
- DAVA 2000
- ORGO 1985
- Country
- DAVA United Kingdom
- ORGO United States
- Employees
- DAVA N/A
- ORGO N/A
- Industry
- DAVA EDP Services
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- DAVA Technology
- ORGO Health Care
- Exchange
- DAVA Nasdaq
- ORGO Nasdaq
- Market Cap
- DAVA 503.6M
- ORGO 539.1M
- IPO Year
- DAVA 2018
- ORGO N/A
- Fundamental
- Price
- DAVA $6.58
- ORGO $6.15
- Analyst Decision
- DAVA Buy
- ORGO Buy
- Analyst Count
- DAVA 8
- ORGO 3
- Target Price
- DAVA $18.14
- ORGO $7.33
- AVG Volume (30 Days)
- DAVA 1.3M
- ORGO 2.8M
- Earning Date
- DAVA 11-11-2025
- ORGO 11-06-2025
- Dividend Yield
- DAVA N/A
- ORGO N/A
- EPS Growth
- DAVA 58.26
- ORGO N/A
- EPS
- DAVA 0.25
- ORGO N/A
- Revenue
- DAVA $1,015,391,026.00
- ORGO $465,218,000.00
- Revenue This Year
- DAVA N/A
- ORGO $2.51
- Revenue Next Year
- DAVA $3.81
- ORGO $25.45
- P/E Ratio
- DAVA $25.81
- ORGO N/A
- Revenue Growth
- DAVA 1.07
- ORGO 2.24
- 52 Week Low
- DAVA $6.52
- ORGO $2.61
- 52 Week High
- DAVA $34.94
- ORGO $7.08
- Technical
- Relative Strength Index (RSI)
- DAVA 29.78
- ORGO 71.85
- Support Level
- DAVA $6.64
- ORGO $3.84
- Resistance Level
- DAVA $7.36
- ORGO $7.08
- Average True Range (ATR)
- DAVA 0.44
- ORGO 0.42
- MACD
- DAVA -0.24
- ORGO 0.25
- Stochastic Oscillator
- DAVA 0.74
- ORGO 70.28
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.